Use of argatroban during multi-organ procurement: pharmacokinetics and sequelae in recipient of transplanted liver.
This report illustrates potential concerns regarding the administration of Argatroban (AGN), a small molecule, direct thrombin inhibitor, within the setting of multi-organ procurement (MOP). Herein, we outline the case of a large AGN bolus to the donor during MOP, and the passive transfer of a coagulopathy to the recipient of the transplanted liver. From this, we conclude that caution should be exercised when AGN is used in the setting of MOP.
Schwartz
J J
JJ
Section of Transplantation, Department of Surgery, School of Medicine, University of Utah, Salt Lake City, UT 84132, USA. jason.schwartz@hsc.utah.edu
Hatch
J M
JM
Book
Z
Z
Lonardo
N
N
Hutson
W R
WR
Sorensen
J B
JB
D000991:Antithrombins / Q000009:adverse effects / Q000493:pharmacokinetics*; D001120:Arginine / Q000031:analogs & derivatives; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000628:therapy; D017707:Erythrocyte Transfusion; D006084:Graft Rejection / Q000209:etiology*; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D008099:Liver / Q000378:metabolism*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time; D010875:Pipecolic Acids / Q000009:adverse effects / Q000493:pharmacokinetics*; D017713:Platelet Transfusion; D011517:Prothrombin Time; D013449:Sulfonamides; D014018:Tissue Distribution; D014019:Tissue Donors; D009927:Tissue and Organ Procurement; D055815:Young Adult
D000991:Antithrombins; D010875:Pipecolic Acids; D013449:Sulfonamides; D001120:Arginine; C031942:argatroban